cp wire

CP Wire Articles

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, reported on 4/25/18 new positive magnetic resonance efficacy results showing slowed disease progression... read more

Wed, 04/25/18 - 07:39 pm
Canadian STEMCELL Technologies Receives $45 Million Government Funding for Advanced Manufacturing Facility

STEMCELL Technologies  announced on 4/25/18 a $45 million joint funding agreement between the Governments of Canada and British Columbia to help the company build a state-of-the-art advanced... read more

Wed, 04/25/18 - 04:47 pm
Is Vaxart One to Watch...Maybe?

Vaxart is a clinical stage biopharmaceutical company that seems to hold a great deal of promise. They are developing several oral tablet vaccines with the most promising being a vaccine for... read more

Wed, 04/25/18 - 01:59 pm
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
  • AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable... read more
Wed, 04/25/18 - 09:46 am
OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation

In June of 2017, OrphoMed announced that they had closed a $39 Million series A round to accelerate development of their lead candidate, ORP-101, IBS-D. On 4/25/18 they announced that the FDA has... read more

Wed, 04/25/18 - 09:18 am

Pages